Tang Capital Management OPRX Position
ExitedTang Capital Management exited their position in OptimizeRx Corp (OPRX) in Q4 2025, after holding the stock for 5 quarters.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
1 other tracked fund also holds OPRX.
Tang Capital Management OPRX Position History
Frequently Asked Questions
Does Tang Capital Management own OPRX?
No. Tang Capital Management exited their position in OptimizeRx Corp (OPRX) in Q4 2025. They previously held the stock for 5 quarters.
How many hedge funds own OPRX?
1 specialist biotech hedge fund currently holds OPRX, including Casdin Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy OPRX?
Tang Capital Management's position in OPRX was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's OPRX position increasing or decreasing?
Tang Capital Management completely exited their OPRX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OPRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →